| 1.66 -0.34 (-17%) | 12-01 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 2.5 |
1-year : | 3.83 |
| Resists | First : | 2.14 |
Second : | 3.27 |
| Pivot price | 0.87 |
|||
| Supports | First : | 0.3 |
Second : | 0.25 |
| MAs | MA(5) : | 1.96 |
MA(20) : | 0.73 |
| MA(100) : | 0.82 |
MA(250) : | 3.37 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 63 |
D(3) : | 73.4 |
| RSI | RSI(14): 62.3 |
|||
| 52-week | High : | 11.52 | Low : | 0.25 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ RDHL ] has closed below upper band by 26.9%. Bollinger Bands are 485% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.89 - 1.9 | 1.9 - 1.91 |
| Low: | 1.56 - 1.57 | 1.57 - 1.58 |
| Close: | 1.64 - 1.66 | 1.66 - 1.67 |
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
Thu, 30 Nov 2023
Healthcare Stocks Moving Thursday: SNGX, NBSE, IMGN, AMPE, VVOS, RDHL, MOTS, ARWR - InvestorsObserver
Thu, 30 Nov 2023
Why Is Redhill Biopharma (RDHL) Stock Down 27% Today? - InvestorPlace
Thu, 30 Nov 2023
Why Salesforce Shares Are Trading Higher By Over 9%; Here Are ... - Investing.com UK
Thu, 30 Nov 2023
Premarket Mover: RedHill Biopharma Ltd (RDHL) Down 21.53% - InvestorsObserver
Wed, 29 Nov 2023
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and ... - InvestorPlace
Tue, 28 Nov 2023
U.S. stocks higher at close of trade; Dow Jones Industrial Average ... - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers—Specialty & Generic
|
|
| Shares Out | 11 (M) |
| Shares Float | 1,110 (M) |
| Held by Insiders | 4.3 (%) |
| Held by Institutions | 11.1 (%) |
| Shares Short | 294 (K) |
| Shares Short P.Month | 17 (K) |
| EPS | -8 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.09 |
| Profit Margin | 32.3 % |
| Operating Margin | -245.5 % |
| Return on Assets (ttm) | -17.2 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -90.2 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 3.22 |
| EBITDA (p.s.) | -2.18 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -26 (M) |
| Levered Free Cash Flow | -39 (M) |
| PE Ratio | -0.21 |
| PEG Ratio | 0 |
| Price to Book value | 1.52 |
| Price to Sales | 0.51 |
| Price to Cash Flow | -0.71 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|